Anaphylactic reaction to recombinant insulin-like growth factor-I.
Mecasermin [rDNA] (Increlex; Tercica, Inc.) is recombinant insulin-like growth factor-I (IGF-I) that has been approved to treat growth failure in children with severe primary IGF-I deficiency. Serious allergic reactions related to Increlex therapy have not been reported. We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.
Torjusen
Erika
E
Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA.
Calderon
Jose
J
Rivkees
Scott A
SA
D000293:Adolescent; D000707:Anaphylaxis / Q000139:chemically induced*; D006130:Growth Disorders / Q000188:drug therapy*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000009:adverse effects* / Q000172:deficiency; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects*
D036341:Intercellular Signaling Peptides and Proteins; D011994:Recombinant Proteins; C065700:myotrophin; D007334:Insulin-Like Growth Factor I